Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent RE42015 N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections

Patent RE42015 was granted and assigned to Pharmasset on December, 2010 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Inventor Names

Junxing Shi0

Kyoichi A. Watanabe0

Michael J. Otto0

Date of Patent

December 28, 2010

Patent Application Number

11821076

Date Filed

June 21, 2007

Patent Citations Received

US Patent 12084473 β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

0

US Patent 11690860 Treatment of HCV infected patients with cirrhosis

0

US Patent 11707480 Highly active compounds against COVID-19

0

US Patent 11975016 2′-substituted-N

0

US Patent 12006340 Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus

0

Patent Primary Examiner

Patent abstract

The present invention is directed to a compound, method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N4-acylcytosine-1,3-dioxolane and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent RE42015 N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool